Hormonal
Metformin therapy reduces the risk of developing type 2 diabetes in patients with prediabetes, with the greatest preventive effect observed in individuals with higher baseline glycated hemoglobin (HbA1c) and a history of gestational diabetes.
If you have prediabetes, especially if your HbA1c is on the higher side (6.0-6.4%) or you had gestational diabetes, metformin is a proven, safe option to prevent type 2 diabetes. It works by improving how your liver handles glucose and insulin. It does not cause low blood sugar, making it a low-risk preventive tool when lifestyle changes alone are not enough.
максимальный эффект от превентивной терапии метформином наблюдался у пациентов с исходно более высокими значениями ГПК (6,1–6,9 ммоль/л), HbA1c (6,0–6,4%) и с гестационным СД в анамнезе
Why this rating
Based on large-scale randomized controlled trials (DPP, DPPOS) cited in the review, though the paper itself is a review article.
Source
Modern aspects for preventive therapy of type 2 diabetes mellitus
В. В. Салухов et al. · Meditsinskiy sovet = Medical Council · 2019
DOI 10.21518/2079-701x-2019-4-6-13
More from this paper
- Acarbose, an alpha-glucosidase inhibitor, reduces the risk of developing type 2 diabetes in patients with impaired glucose tolerance, but its effectiveness is lower than that of lifestyle modification and metformin.Good
- Pioglitazone, a thiazolidinedione, significantly reduces the risk of developing type 2 diabetes in patients with impaired glucose tolerance and stabilizes beta-cell function, with a favorable cardiovascular safety profile compared to rosiglitazone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →